Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. (Q34616904)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

review article

1 reference

stated in

Europe PubMed Central

title

Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

main subject

ovarian cancer

1 reference

based on heuristic

inferred from title

author

Susan J Keam

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

author name string

Natalie J Carter

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

publication date

1 February 2010

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

published in

Drugs

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

volume

70

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

issue

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

page(s)

355-376

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

cites work

Marine metabolites overcoming or circumventing multidrug resistance mediated by ATP-dependent transporters: a new hope for patient with tumors resistant to conventional chemotherapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.2165%2F11202860-000000000-00000

retrieved

21 January 2018

Diagnosis and management of epithelial ovarian cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.2165%2F11202860-000000000-00000

retrieved

21 January 2018

7505 ORAL Personalized therapy with trabectedin (Yondelis®) in advanced pre-treated sarcomas

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.2165%2F11202860-000000000-00000

retrieved

21 January 2018

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ET-743.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biomarkers in cancer staging, prognosis and treatment selection

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiological aspects of soft tissue sarcomas (STS)--consequences for the design of clinical STS trials.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ecteinascidin-743 inhibits activated but not constitutive transcription.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soft-tissue sarcomas in adults

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of homologous recombination in trabectedin-induced DNA damage

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current management strategies for ovarian cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro radiosensitisation by trabectedin in human cancer cell lines.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin--a targeted chemotherapy?

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival from cancer of the ovary in England and Wales up to 2001

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ET-743: a novel agent with activity in soft-tissue sarcomas

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ovarian cancer. Clinical practice guidelines in oncology

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20166769

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.2165/11202860-000000000-00000

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

Dimensions Publication ID

1002180227

0 references

PubMed publication ID

20166769

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20166769

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166769%20AND%20SRC:MED&resulttype=core&format=json

retrieved

18 January 2020

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34616904&oldid=2196868971"